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A B S T R A C T
The potential of non-replicating Newcastle Disease Virus (NDV) as an adjuvant for DNA vaccination remains to
be elucidated. To assess the therapeutic effects of DNA vaccine (HPV-16 E7 gene) adjuvanted with NDV, female
C57/BL6 mice were inoculated with murine TC-1 cells of human papillomavirus (HPV)-related carcinoma, ex-
pressing human papillomavirus 16 (HPV-16) E6/E7 antigens, and immunized with DNA vaccine alone or pre-
treated with NDV. One week after third immunization, Cytotoxic T lymphocytes (CTLs), splenocyte proliferation,
cytokine balance (IFN-γ, IL-4 and IL-12 secretions) and intratumoral expression of cytotoxicity related proteins
in tumor lysates were investigated.
The results showed that treatment with non-replicating NDV prior to DNA vaccine induced tumor-specific
cytolytic and splenocyte proliferation responses. The levels of cytokines IL-12, IL-4 and IFN–γ after treating with
combined E7-DNA -non-replicating NDV (NDV-DNA Vaccine) were significantly higher than those of control
groups. The intratumoral granzyme B and Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL)-
mediated apoptosis was also significantly increased. Tumor therapeutic experiments showed that the NDV
pretreatment could reduce the tumor progression of established E7-expressing TC-tumors. Taken together these
data suggest that the significant antitumor responses evidenced during treatment with non-replicating NDV prior
to DNA vaccine are due, in part, to strong E7-induced cellular immunity and enhanced expression of cytotoxicity
related proteins in the tumor microenvironment. These observations indicated the potential of non-replicating
NDV as an adjuvant for enhancing therapeutic DNA vaccines -induced immunity and antitumor responses.
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1. Introduction
Cervical cancer is the second most common cancer in women
worldwide and the leading cause of cancer deaths (Waggoner, 2003).
Chronic infection of the reproductive tract with human papillomavirus
(HPV) is usually the cause of cervical cancer, and the continued ex-
pression of the E6 and E7 oncogenes of high-risk HPVs is required for
the maintenance of the proliferative state of cervical cancer cells (Bosch
and de Sanjose, 2003).
Immunotherapy has become an increasingly appealing therapeutic
strategy for patients with cancer. Immunotherapies against tumors in-
clude various approaches, ranging from cancer vaccines to oncolytic
viruses that have been evaluated in both pre- clinical and clinical in-
vestigations (Farkona et al., 2016).
Among different types of cancer vaccines, DNA vaccines have
emerged as an attractive strategy for antigen-specific cancer im-
munotherapy due to their simplicity, stability, safety, and their capacity
to induce a broad spectrum of cellular and humoral immune responses
(Yang et al., 2014).
Despite all the benefits, DNA vaccines suffer from limited ther-
apeutic effects due to low transfection efficiency in vivo. Therefore, it is
important to devise new methods to augment the intensity and duration
of vaccine-induced immune responses and to confer a protective anti-
tumor immune response. Development of novel immunostimulants is
likely to meet many challenges in modern vaccinology (Gableh et al.,
2016; Sajadian et al., 2014).
HPV therapeutics like DNA vaccines are well tolerated to induce
antigen-specific immunity through the viral antigen processing and
presentation in antigen presenting cells (Lin et al., 2010). Although
immunostimulatory agents are a promising approach to improve cancer
treatment, the role of non-human viruses in anti-tumor im-
munomodulation has been investigated, and potent im-
munomodulatory activities have been reported for some viruses
(Prestwich et al., 2008).
Treatment of a tumor with a virus leads to immunogenic cancer cell
death (ICD) induction, resulting in the release of danger signals or
pathogen/damage-associated molecular patterns (P/DAMPs)
(Workenhe and Mossman, 2014), along with the reduced intratumoral
immunosuppressive environment and increased cross-priming of
tumor-associated antigens (Alemany, 2014). The treatment can convert
an immunosuppressive tumor microenvironment to an im-
munostimulatory status. Considering these immunostimulatory actions,
it has been hypothesized that whether non-replicating virus can be
combined with other immunotherapeutic strategies including cancer
vaccines (Bastin et al., 2016).
Newcastle Disease Virus (NDV) is a RNA virus with long known
cancer specific inducing apoptotic cell death activities (Szeberenyi
et al., 2003). Post-oncolytic activity of NDV, i.e. ICD, suggests this virus
as a potent agent to overcome tumor-induced immunosuppressive en-
vironment (Schirrmacher, 2015). As the viruses may have side effects to
normal cells, tumor selective oncolysis of the viruses is not always
possible (Wong et al., 2010). Although the antitumoral effects of live or
inactivated NDV have been studied, we describe here the adjuvant ef-
fects of non-replicating NDV in combination with cancer vaccine
against TC-1 tumor induction. The NDV components like cytosolic viral
long RNA, mRNA, fusion protein (F) and hemagglutinin neuraminidase
(HN) are all involved in and can trigger tumor cell death through either
immune induction or immune independent apoptosis (Mansour et al.,
2011; Ni et al., 2010). The NDV-induced ICD optimizes presentation of
tumor associated antigens (TAA) and facilitates antitumor immune re-
sponses (Schirrmacher, 2015).
Naturally occurring NDV strains induced limited tumor-specific
immunity, but play an important role in modulation of the host immune
response and recognition of vaccine antigens (Zamarin et al., 2009). It
has been shown that immunized mice with NDV LaSota strain leads to
production of anti-viral neutralizing anti-bodies, which cause superior
anti-tumoral effects and prolonged median survival of treated animals
(Chaurasiya et al., 2018; Ricca et al., 2018). It is also known that het-
erologous prime-boosting strategy, in which the prime response is sti-
mulated by a virus enhances antiviral immune responses (Bridle et al.,
2009). Therefore, in the current study we have aimed to evaluate
cancer immunotherapy using a therapeutic tumor-associated antigen
expressing E7 DNA vaccine after priming with lentogenic LaSota (La)
NDV strain (Romer-Oberdorfer et al., 2003) as adjuvant. The results of
the current study showed that HPV-16 E7 DNA vaccine-induced tumor
protection was significantly enhanced by pre-treating the tumor with a
non-replicating NDV strain.
2. Materials and methods
2.1. NDV preparation
The LaSota strain of NDV was obtained from Razi Institute of Serum
and Vaccine Research Center, Tehran, Iran. Virus was propagated of 10
day-old embryonated specific pathogen-free (SPF) eggs and purified
from the chorioallantoic fluid. The number of infectious virus particles
in a preparation was evaluated by using plaque forming assay at
40–72 h post infection (Kournikakis and Fildes, 1988). NDV strain La-
Sota (108 pfu) was inactivated at UV light power of 50mW/cm2 for
5min at 5 cm distance from the UV lamp just before use. In addition,
the completeness of UV inactivation of NDV strain LaSota was con-
firmed by plaque forming assay on Vero cell line (Ghrici et al., 2013;
Walter et al., 2012). The results showed that The UV-inactivated NDV
did not form any plaques on Vero cells.
2.2. Cell lines
The murine lung cancer cell line, TC-1, was derived from primary
lung epithelial cells from C57BL/6 mice. The cell line was immortalized
with HPV-16 E6 and E7 and transformed with the c-Ha-ras oncogene
and purchased from the National Cell Bank of Iran (Pasteur Institute of
Iran).
The cell line was maintained in complete RPMI 1640 medium
(Gibco BRL, Gaithersburg, MD, USA) supplemented with 10% fetal
bovine serum (FBS) (Gibco, Rockville, MD), 2.5mM 2-mecaptoethanol
(Invitrogen, Carlsbad, CA), 0.5 mM sodium pyruvate (Sigma Aldrich,
Germany), 2 mM L-glutamate (Invitrogen, Carlsbad, CA), and 100 U/
mL of penicillin- 100mg/L streptomycin (Sigma, St. Louis,. MO, USA)
(Moeini et al., 2017).
The murine thymoma cell line EL4 (murine T-cell lymphoma of
haplotype H-2b) was cultured (at 37 °C in a humidified atmosphere of
5% CO2 in air) in RPMI 1640 supplemented with 10% FBS.
2.3. Animal bearing tumor
Six - to eight-week-old Female C57BL/6 (H2b) mice were obtained
from the Institute Pasture of Iran (Tehran, Iran). Mice were housed for 1
week before the experiment, given free access to food and water, and
maintained in a 12:12-h light: dark cycle. All experiments were carried
out in accordance with the Animal Care and Use Protocol of Golestan
University of Medical Sciences of Iran.
For tumor induction (Sajadian et al., 2014), six groups of C57BL/6
mice (n=10) were inoculated by subcutaneous (s.c.) injection in the
right flank with 3×105 TC-1 cells in 100 μl PBS.
2.4. DNA vaccine and NDV administration
Plasmids containing HPV-16 E7 gene were constructed for mam-
malian expression in our laboratory previously. Plasmid constructs
were verified by DNA sequencing and gene expression (Sajadian et al.,
2014). Stocks of endotoxin free DNA vaccine and vector control plas-
mids (pcDNA3.1) in 0.1M PBS were purified for vaccination using the
A. Mohebbi et al. Virus Research 261 (2019) 72–80
73
EndoFree® Plasmid Maxi Kit (Qiagen, Hilden, Germany) and dissolved
in endotoxin free Tris-EDTA (TE Buffer - 10mM Tris−HCL, 0.1mM
EDTA, pH 8.0) (Sigma, St. Louis, MO, USA).
One week after tumor induction, animals were randomly divided
into six groups (n=10 in each group). The first two groups were in-
jected with NDV subcutaneously at a dose of 105 pfu/mouse. Twelve
hours later, the E7-DNA vaccine (NDV-DNA vaccine, group I) or
pcDNA3 control vector (NDV-pcDNA, group II) were inoculated (E7
DNA vaccine, 100 μg in 100 μl using subcutaneous administration). The
same procedure of immunization employing the same dose of treat-
ments was used for repeat immunizations on days 14 and 21. Each
animals in groups III (DNA vaccine) and IV (NDV) were respectively
administrated with 100 μg DNA-E7 vaccine and 105 pfu NDV with the
same protocol. PBS and pcDNA3 were injected according the same
protocol into V and VI group as control groups (PBS and pcDNA groups)
(Fig. 1).
Tumor growth was monitored by visual inspection and palpation
one week after TC-1 inoculation. The average mean of all tumor vo-
lumes were calculated and reported in cubic millimeters. Tumor dia-
meters were measured in a blinded, coded fashion twice a week using
two orthogonal dimensions with electronic digital calipers. The tumor
volume was calculated as: (longest diameter) × (shortest diameter) 2)
× 0.5. The formula given for the tumor volume is according to
Carlsson’s formula (Carlsson et al., 1983). Mice were euthanized once
tumors exceeded a diameter of 1 cm or became necrotic to the animals.
Tumor growth was followed for a period of 6 weeks after the inocula-
tion. All values were expressed as means ± S.D. Three mice per group
were sacrificed one week after the last boost and the spleens were re-
moved aseptically for immunological tests. Schematic overview of
study design has been shown in Fig. 1.
2.5. Cytokine assay
One week after the third immunization, spleens from the im-
munized mice were removed and red blood cells were cleared by in-
cubation in lysis buffer (0.15M NH4Cl, 1 mM KHCO3, 0.1mM
Na2EDTA, pH 7.2) for 5min at 37 °C. Mononuclear cells at a con-
centration of 2× 105 cells per well were incubated in 24-well plates for
3 days in RPMI1640 supplemented with 10% FBS, 1% L-glutamine, 1%
HEPES, 2.5mM 2-mercaptoethanol, and pulsed with E7-specific H-2Db
CTL epitope at a concentration of 1 μg/ml (Biomatik, Ontario,
Canada,> 99% purity) (Gableh et al., 2016) and at 37 °C in 5% CO2.
IFN- γ, IL-4 and IL-12 secretion were evaluated 48 h after stimulation.
Culture supernatant samples were collected and assayed for the pre-
sence and titer of cytokine-specific polyclonal antibodies conjugated to
horseradish peroxidase were detected using TMB (tetra-
methylbenzidine) substrate using commercially available Quantikine
Mouse IFN- γ, IL-4 and Il-12 assays (R&D Systems Inc., Minneapolis,
Minn, USA) according to the manufacturer’s instruction. The plates
were read at 450 nm, and values were expressed as optical densities. All
tests were performed in triplicate.
2.6. Lymphocyte proliferation assay (LPA)
One week after third immunization, a single-cell suspension of
mononuclear cells obtained from immunized mice was used for the
lymphocyte proliferation assay (LPA). The preparations were cultured
in in complete medium, and incubated in the presence of E7-specific H-
2Db CTL epitope (1 μg/ml) per well at 37 °C in 5% CO2. Five μg/ml T
cell mitogen phytohemagglutinin (PHA) (Sigma Chemicals, St. Louis,
MO, USA) was used as the positive control. After 3 days, 5 μg/ml of
MTT [3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide
(Sigma Chemicals, St. Louis, MO, USA) was added to each well and
incubated for 5 h at 37 °C in 5% CO2. DMSO (100 μl) was added to
dissolve formed formazan crystals. Then, optical density was read at
540 nm (and reference at 630 nm) and the results expressed as a sti-
mulation index (SI). The SI was determined as follows:
=SI OD stimulated culture
OD unstimulated culture
All tests were done in triplicate for each mouse.
2.7. Cytotoxicity assay
One week after last booster, the mice (three mice of each group)
were sacrificed and their splenocytes were isolated. For each sample
obtained from individual mice, single-cell suspensions of mononuclear
cells (used as the effector cells) were cultured in RPMI 1640 medium
with washed EL4 target cells (a mouse lymphoma cell line derived from
C57BL/6 (MHC- H-2b); ATCC TIB-39, from the National Cell Bank of
Iran (Pasteur Institute, Tehran)) at various effector-to-target cell (E/T)
ratios (25:1, 50:1, 100:1) and in 96-well flat-bottom plates for 4 h in
complete medium. For preparation of the target cells, EL4 cells were
stimulated with H2b-restricted epitope E7-specific CTL epitope
49RAHNIVTF57 at a concentration of 1 μg/ml (Biomatik, Ontario,
Canada,> 99% purity) (specific antigen) and then incubated for 4 h.
The ectodomain of matrix protein 2 (M2e) of influenza A virus synthetic
peptide was used as irrelevant peptide and a negative control. After
centrifugation, the supernatants (50 μl/well) were transferred to the 96-
well flat-bottom plates (Corning, Corning, NY, USA), and lysis of target
cells was determined by measuring lactate dehydrogenase (LDH) re-
lease using a LDH cytotoxicity detection kit (Takara Company, Shiga,
Japan). Several controls were used for the cytotoxicity assay. The ‘high
control’ was used for measuring total LDH release from the target cells
(all EL4 cells were lysed with medium containing 1% Triton X-100).
The ‘low control’ was used for measuring natural release of LDH from
the target cells (which was obtained by adding EL4 cells only to the
medium).
Fig. 1. Schematic overview of study design:
The time scale at the top represents the days
after TC-1 inoculation, vaccination, im-
munological assays and tumor volume calcu-
lation. At time zero mice were inoculate with
TC-1 tumor. Mice were immunized by sub-
cutaneous injection with different treatments.
Three mice in each of 6 groups were sacrificed
at the 28-day time points. Spleen were col-
lected for immunological assays.
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The LDH-mediated conversion of tetrazolium salt into a red for-
mazan product was measured at 490 nm (Gableh et al., 2016; Naderi
et al., 2013). The percentage of specific cytolysis was determined by the
following formula:
=
×
Cytotoxicity Test sample effector low control
high control low control
% ( )
100
2.8. Preparation of tumor homogenate
To evaluate the cytokine levels in tumor microenvironment, the
tumor homogenate was prepared for all experimental tumor-bearing
mice. Briefly, TC-1 tumors were harvested and tumor tissue extracts
were prepared by mechanical homogenization and sonication of
100mg of tumor in 500mL of lysis buffer (50mM Tris HCl, pH 7.4,
150mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100, 1% sodium
deoxycholate, and 1mM phenyl-methane-sulfonyl fluoride [PMSF]
(Sigma-Aldrich, St. Louis, Missouri, USA). The samples were then
homogenized and centrifuged and supernatants were removed and fil-
tered through a 0.45 μm filter; afterwards, the protein concentration
was measured by the Bradford method (Sajadian et al., 2014).
2.9. Intratumoral cytokine assay
To detect the cytotoxic expression in the tumor microenvironment,
tumor homogenates were used for the ELISA assay. For the assay,
protein concentration of tumor homogenate samples were adjusted to
2mg/ml with PBS and then the level of intratumoral mouse TRAIL
(Tumor Necrosis Factor Related Apoptosis Inducing Ligand) was de-
termined using an mouse DuoSet ELISA Kit (R&D Systems Inc.,
Minneapolis, MN, USA). Granzyme B expression was also evaluated
using a Mouse Granzyme B ELISA Ready-SET-Go (eBioscience, Inc. San
Diego, CA, USA) according to the manufacturer’s instruction.
2.10. Statistical analysis
To compare results between the different groups one-way ANOVA
was used. The statistical software SPSS version 16.0.0 was used for data
analyses. Differences were considered statistically significant at
p<0.05.
3. Results
3.1. Lymphocyte proliferation
Evaluation of lymphocyte proliferation in the experimental groups
was carried out with a MTT/ELISA-based method. Two DNA vaccinated
groups (DNA vaccine and NDV-DNA vaccine groups) showed significant
differences when compared with NDV, NDV-pcDNA ((P < 0.05), PBS
and pcDNA control groups (P < 0.001). Immunization with combined
E7-DNA -non-replicating NDV (NDV-DNA vaccine) significantly in-
creased lymphocyte proliferation compared with NDV and DNA treated
groups (P < 0.001). The results also revealed that DNA vaccine alone
significantly increased stimulation index compared to the NDV and
NDV-pcDNA groups (P < 0.05). There was no significant difference
between the control groups (NDV-pcDNA, NDV, PBS and pcDNA)
(P > 0.05) (Fig. 2). These results suggest that inoculated with non-
replicating NDV can enhance the antigen-specific T-cell response of
DNA vaccine.
3.2. CTL assay
T lymphocyte cytolytic activity was measured with release of
Lactate dehydrogenase assay (LDH). The effector: target cell ratio up to
the maximum ratio of 100:1 was used in the present study (Fig. 3A).
The results of LDH release assay as a criterion of CTL activity index
indicate that injection of combined E7-DNA -non-replicating NDV
(NDV-DNA vaccine group) significantly augmented CTL activity com-
pared with the control groups (NDV-pcDNA, NDV, PBS and pcDNA)
(p < 0.001. Also treatment with combined E7-DNA-non-replicating
NDV (NDV-DNA vaccine group) led to a 22% increase of CTL responses
versus DNA vaccine alone (P < 0.01). No significant difference be-
tween the control groups (NDV, PBS and pcDNA) was observed)
(Fig. 3B). Irrelevant peptide as a negative control showed no influence
on E7-specific cytotoxicity between different groups. The results
showed the NDV ability to enhance the antitumor cytolytic activity of
DNA vaccine.
3.3. Cytokine assay
To further determine the effect of NDV on DNA vaccine-induced
immune response, the expression of cytokines were measured in spleen
cells. Assessment of the cytokines in the experimental groups indicate
that combined E7-DNA -non-replicating NDV (NDV-DNA vaccine
group) or immunization with DNA vaccine alone significantly increased
IFN- γ and IL-12 secretion compared with the control groups (NDV-
pcDNA, NDV, PBS and pcDNA3) (p < 0.001) (Fig. 4 A, C). In spleen
cells, higher IL-4 production was seen in DNA vaccinated mice com-
pared with negative control groups (PBS and pcDNA) (Fig. 4B), whereas
this was not seen compared with NDV and NDV-pcDNA treated mice
Furthermore, stimulated IFN-γ, IL-12 and IL-4 production were higher
in the NDV-DNA vaccine group compared to DNA vaccine group
(P≤ 0.001). Therefore, immunization with DNA vaccine combined
with NDV as adjuvant promoted IFN-γ, IL-4 and IL-12 production, re-
sulting in an enhanced cellular immune response.
3.4. Tumor therapy experiment
In the therapeutic model, all mice that had formed a palpable tumor
(at day 7) were vaccinated on days 7, 14 and 21 with the indicated
regimens and followed for tumor growth and survival over six weeks.
Over a total of six weeks, it was demonstrated that all mice in the
NDV-DNA vaccine group controlled tumor growth significantly better
than all other groups (Fig. 5). Compared with a moderate inhibitory
effect of DNA vaccine on tumor growth, NDV adjuvant increased the
antitumor effect of the DNA vaccine at 42 days post-tumor- inoculation
(p < 0.001). Note that the mean size of the tumors (∼185 mm3) is
lower in NDV-DNA vaccine group than in DNA-vaccinated mice (∼365
mm3). In contrast, the use of NDV as a monotherapy and NDV -pcDNA
administration had no inhibitory activity. These data indicate that
vaccination with DNA vaccine in combination with low-dose non-re-
plicating Newcastle disease virus induced a strong immune response,
which translated into a protective antitumor response.
3.5. Tumor microenvironment assay
To assess whether the resulting effects of NDV-DNA vaccine on
tumor protection could be correlated with the tumor microenvironment
factors, the expression of cytotoxicity related proteins (TRAIL and
granzyme B) were determined in tumor lysates by ELISA assay
(Table 1).
NDV-DNA vaccine group demonstrated a significant increase in
granzyme B and TRAIL expression compared to pcDNA3, PBS, NDV-
pcDNA and NDV control groups (p < 0.001).
DNA vaccinated mice induced significant increase in intratumoral
granzyme B and TRAIL expression than control groups, however, the
change of TRAIL expression was not statistically significant compared
to NDV and NDV-pcDNA3 groups. Furthermore, the results showed that
in the tumor lysate that received NDV-DNA vaccine, the expression of
granzyme B and TRAIL were 2.07 and 1.9 fold greater than the DNA
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vaccine group (p < 0.01). These data suggest that DNA vaccine, HPV-
16 E7 gene, that induces intratumoral granzyme B and TRAIL-mediated
apoptosis in the context of Tc-1 tumor, can trigger therapeutic T cell
and antitumor responses if mice are pretreated with low-dose non-re-
plicating NDV.
4. Discussion
Virus-induced antitumor responses occur by different mechanisms
including direct killing of the tumor cells, induction of tumor cell
apoptosis and stimulation of host immune response. Previous study has
shown that inactivated and replication-defective NDV demonstrated
high rates of lysis in apoptotic tumor cells and great antitumor effects
(Yang et al., 2007). The study presented that viral replication does not
cause virally induced apoptosis. Furthermore, it has been shown that
intratumoral injection of inactivated, replication-defective, Sendai virus
particles induced inhibitory effects on the growth of CT26 murine colon
carcinoma cells in BALB/c mice (Kurooka and Kaneda, 2007). These
data may indicate that antitumor responses mediate in part the in-
creased stimulation of tumor-specific cytotoxic CD8 (+) T cells and
inhibition of regulatory T cells, which need to be investigated (Kurooka
and Kaneda, 2007). In another study, UV-inactivated, replication-de-
fective Sendai virus particles injected into murine colon carcinoma
(CT26) tumors growing in syngeneic BALB/c mice induced systemic
antitumor immunity by enhancing NK cell cytotoxicity through se-
creting IFN-β and eradicated 60%–80% of the tumors in renal cell
carcinoma tumor-bearing mice (Fujihara et al., 2008). Furthermore, it
was demonstrated that low dose of avirulent lentogenic NDV strain,
Ulster, cause activation of CTL by augmenting of IFN-α/β in metastatic
murine lymphoma tumor model (von Hoegen et al., 1990). However,
the adjuvant effects of lentogenic NDV on DNA vaccination are not fully
understood. Therefore, in the present study, as higher titers of live
viruses may cause damages to normal cells (Walter et al., 2012), as well
as to evaluate adjuvant effects of lentogenic strain of NDV (Voit et al.,
2003), we aimed to analyze immunogenic NDV as an adjuvant for HPV-
16 E7 DNA vaccine. Adjuvants can enhance the innate and adaptive
immune response to vaccines by interacting with cellular pattern re-
cognition receptors (PRRs) that recognize pathogen-associated
molecular patterns (PAMPs). Several PRRs have been identified in
mammals, of which toll-like receptors (TLRs), nucleotide-binding oli-
gomerization domain NOD-like receptors (NLRs) and retinoic acid-in-
ducible gene I (RIG-I)-like receptors (RLRs) are the most reported
(Vasou et al., 2017). Viruses, as previously shown, can be used as im-
mune activator adjuvant for the vaccines (Altinoz et al., 2017; Anziliero
et al., 2014). Activation of PRRs by the immunostimulatory PAPMs
(Workenhe and Mossman, 2014), as well as presentation of TAAs to
host immune system (Schirrmacher, 2015), makes NDV a candidate
adjuvant, enabling both arms of immune systems for generation of
antitumor responses, or immunological tumor cell death (ICD) (Bastin
et al., 2016; Zhao and Liu, 2012).
The description is compatible with previous findings of Kang et al.
They showed that inactivated influenza virus can be used as adjuvant
for mucosal immunity (Kang et al., 2004). It has been also reported that
a lower dose of NDV, as an adjuvant, will lead to completely regression
of tumor cells (Lorence et al., 1994). Therefore, local injection of low
dose NDV strain was used to assess tumor-specific immune response.
In the present study, it was demonstrated that antitumor vaccina-
tion with a DNA vaccine expressing a tumor-associated antigen E7 from
human papillomavirus-16 can be significantly enhanced by treatment
with NDV strain. Our results demonstrated that the combination of
adjuvanted DNA vaccine with NDV strain conferred strong antitumor
responses and suppressed tumor growth in tumor cell (TC-1)-bearing
mice. In addition to driving the proliferation of tumor-specific spleno-
cytes, this DNA vaccine adjuvanted with NDV stimulated specific cell
mediated immune responses through the induction of high splenic IFN-
γ and also in inducing E7-specific IL-4 production. In parallel with these
results, the splenocyte-derived T cell killing assay also showed cytotoxic
activities of cytolytic T lymphocytes against EL4 target cells stimulated
with H2b-restricted epitope E7-specific CTL epitope that correlated
with enhanced inhibition of the growth of established TC-1 tumor in
comparison with treatments using the single agents alone. CTL are
generated from precursor T cells following stimulation with cognate
peptide presented on target cells in the presence of adequate costimu-
latory signals and CD4 T-cell help. It has been shown that increased CTL
activities are due to CD8+T cells as a result of cell-cell interaction
induced by NDV major immunogenic hemagglutinin-neuraminidase
Fig. 2. Lymphocyte proliferation of experimental
groups according to stimulation index (SI). Single
splenocyte suspension was isolated one week
after the last booster immunization, plated in
triplicate in a 96-well plate and stimulated in
vitro with HPV-16 E7 epitope. Stimulation index
was calculated for all groups. Values are the
mean ± SD of the mean for the experiments. ***
(p < 0.001) indicate statistically significant dif-
ference between NDV-DNA vaccine group com-
pared with the other groups as determined by
one way ANOVA. * (P < 0.05) shows a statisti-
cally significant difference between the indicated
groups, as determined by one-way ANOVA. The
graph also shows the statistically significant dif-
ferences between all treatment groups (NDV-
DNA vaccine, DNA vaccine, NDV and NDV-
pcDNA with PBS and pcDNA3 control groups
(p < 0.001).
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(HN) protein (Sui et al., 2010). Besides, combined E7-DNA -non-re-
plicating NDV (NDV-DNA vaccine group) resulted in enhanced ex-
pression of granzyme B and TRAIL in the tumor microenvironment of
Tumor-bearing mice.
Adjuvant effects of low-dose non-replicating NDV for triggering
innate immune responses may also elucidate the improved efficacy of
the DNA vaccine for inducing E7-specific acquired responses in com-
parison with DNA vaccine alone. Although more experiments with the
combined treatment are needed to confirm this hypothesis, our study
suggest that PAMP produced by NDV, in combination with DNA vac-
cine, is likely to enhance IL-12 secretion.
IL-12 is an APC-derived cytokine that stimulates T cells and NK cells
to secrete IFN-γ and augments the proliferation and CTL activity of
these cells. In addition to its important role in the regulation of innate
responses and the Th1 lymphocytes, previous study has suggested that
IL-12 is an effective anti-cancer factor against tumors (Tugues et al.,
2015; Weiss et al., 2007). Thus, the combined recognition of DNA
vaccine and NDV antigens could represent definitive recognition of E7
antigen with an amplified immune response. Meanwhile, our results
also showed that the DNA vaccine and NDV groups induced significant
cellular immune response compared with control groups.
In parallel with the current results, we have previously demon-
strated that vaccines targeting E7 oncogene provide the opportunity to
treat HPV-associated malignancies. The studies indicated that DNA
vaccine were able to induce specific cellular immunity, which is critical
in tumor eradication (Gableh et al., 2016). Cytokine assays showed that
activated CTLs could remove tumor cells with E7 antigen (Bahrami
et al., 2014; Ghaemi et al., 2012). Besides, the ability of IFN-γ and IL-12
Fig. 3. The combination of NDV-DNA vaccine
increases CTL response. Analysis of the cyto-
toxic activity of CD8 induced by combined
group of NDV-DNA vaccine. CTL activity of the
lymphocytes from immunized mice (three mice
per group) was measured at different E/T ratios
by LDH release assay kit (TaKaRa) as described
in “Materials and Methods” section. Data are
expressed as the mean percentage ± standard
deviation. Specific lyses of target cells are
shown with non-specific background lysis sub-
tracted. *** (p < 0.001) and ** (p < 0.01)
show statistically significant difference be-
tween the indicated groups as determined by
one way ANOVA. The graph also shows the
statistically significant differences between all
treatment groups (NDV-DNA vaccine, DNA
vaccine, NDV and NDV-pcDNA with PBS and
pcDNA3 control groups (p < 0.001).
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to synergistically augment antitumor immunity (Wigginton et al., 2001)
and their role in reducing tumor growth (Gableh et al., 2016) have been
confirmed. In addition to inducing effective immune responses, it has
been showed that NDV adjuvant of DNA vaccine has increased the in-
duction of TRAIL-mediated tumor cell apoptosis which activates den-
dritic cells (DCs) maturation to present tumor antigens and cross-prime
T-cells. Apoptotic tumor cell death can be immune-stimulatory, as it has
been shown that TRAIL-mediated tumor cell killing contributes to im-
munogenic cell death. The importance of TRAIL was also highlighted by
the observation that functional T cells deficiency could be compensated
by agonistic anti-TRAIL-receptor antibodies in athymic nude mice (van
der Most et al., 2009). Recent evidence suggests that TRAIL is an im-
mune effector molecule and death-inducing cytokine that functions as a
selective anti-tumor agent (Valley et al., 2012). TRAIL can be expressed
by several immune cells including natural killer (NK) cells, T cells,
natural killer T cells (NKT cells), dendritic cells and macrophages
(Falschlehner et al., 2009). Significant TRAIL expression was induced
on the surface of both CD4(+) and CD8(+) cells upon stimulation with
T-cell receptor and type I interferons (IFNs) (Kayagaki et al., 1999).
Achard et al reported that attenuated measles virus-stimulated DCs
activate TRAIL-mediated cell death and convert DCs into cytotoxic ef-
fectors. Acquisition of TRAIL-mediated cytotoxic activity upon ex-
posure to measles virus has been suggested as novel therapeutic
strategy for cancer therapy (Achard et al., 2017). In this regards, it has
been demonstrated that autocrinely produced IFN-γ by CTLs upregulate
TRAIL on CTLs, which can kill the tumor cells via TRAIL expression
(Ciesek et al., 2008). Therefore, TRAIL play an important role in anti-
tumor immune responses (Cretney et al., 2002). These findings support
a model in which non proliferating NDV sensitizes tumor cells for
TRAIL-mediated killing and antigen specific T cell responses.
The results are supported by previous findings that TRAIL secretion
can be induced by nonreplicating viruses. Chaperot et al have shown
that after treatment with inactivated influenza virus, plasmacytoid DCs
(pDCs) express TRAIL and become able to destroy infected and tumor
cells. Induction of TRAIL by the virus is regulated by an autocrine IFN-
αβ loop (Chaperot et al., 2006). The investigation also reported that
treatment with influenza virus can turn pDCs into effective cytotoxic
cells against TRAIL-sensitive targets (Chaperot et al., 2006). Achard
et al also showed that exposure to attenuated measles virus activated
TRAIL-mediated cytotoxic functions in DCs and the finding was re-
ported as new potential therapeutic approaches in cancer therapy
(Achard et al., 2017). Furthermore, it has been described that tumor-
infiltrating pDCs and peritumoral myeloid dendritic cells (mDCs) exert
the cytotoxic responses by secreting TRAIL factor and motivate T cell
immunity by granzyme B production (Jahrsdorfer et al., 2010; Stary
et al., 2007).
5. Conclusions
Given the low immunogenicity of E7 and the role of this oncogene
in altering the immune response against infected cells, our results
suggest that NDV would be a candidate adjuvant to stimulate both in-
nate and adaptive immune responses alongside E7 DNA vaccine. Our
results suggest that fusogenic membrane glycoprotein of NDV may also
contribute to enhance a multitude of DNA vaccine-induced antitumor
immune response.
Our results showed for the first time showed that NDV adjuvanted
DNA vaccine can stimulate tumor-specific immune responses by indu-
cing the cytotoxic mediators and engaging immune effector mechan-
isms. We believe that the results of our investigation can help to de-
velop efficient therapeutic vaccines based on a synergy between local
injection of low dose NDV strain and cancer vaccination.
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